2023 World Conference on Lung Cancer (Posters)-EP11.01. Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression

EP11.01. Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression - PDF(Abstract)

Back to course

Pdf Summary

A study presented at WCLC 2023 explored the predictive biomarkers for the implementation of chemoimmunotherapy in patients with non-small cell lung cancer (NSCLC) and low PD-L1 expression. The study compared the treatment efficacy of first-line chemoimmunotherapy and chemotherapy alone in these patients. A total of 147 patients were enrolled, with 30 receiving chemoimmunotherapy and 147 receiving chemotherapy alone. The results showed that patients who received chemoimmunotherapy had a significantly longer median progression-free survival (PFS) compared to those who received chemotherapy alone (7.3 months vs. 4.9 months). Chemoimmunotherapy was also found to be an independent good prognostic factor for both PFS and overall survival (OS). Subgroup analysis revealed that in patients with low pretreated Neutrophil-to-Lymphocyte Ratio (NLR), chemoimmunotherapy resulted in significantly longer PFS (11.5 months vs. 5.2 months) and OS (40.6 months vs. 10.8 months) compared to chemotherapy alone. The study concluded that a pretreated low NLR could be a predictive biomarker for the implementation of chemoimmunotherapy in NSCLC patients with low PD-L1 expression.

Asset Subtitle

Chian-Wei Chen

Meta Tag

Speaker Chian-Wei Chen

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

WCLC 2023

predictive biomarkers

chemoimmunotherapy

NSCLC

low PD-L1 expression

treatment efficacy

progression-free survival

pretreated NLR

subgroup analysis

implementation